scholarly journals Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke

2012 ◽  
Vol 1 (1) ◽  
pp. 7-12 ◽  
Author(s):  
KIYOSHI KIKUCHI ◽  
NAOKI MIURA ◽  
KO-ICHI KAWAHARA ◽  
YOSHINAKA MURAI ◽  
MOTOHIRO MORIOKA ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Free Radical ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke ◽  
Free Radical Scavenger ◽  
Radical Scavenger

Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone

2018 ◽  
Vol 45 (3-4) ◽  
pp. 115-123
Author(s):  
Masaki Naganuma ◽  
Yuichiro Inatomi ◽  
Makoto Nakajima ◽  
Toshiro Yonehara ◽  
Yukio Ando
Keyword(s):  
Uric Acid ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Free Radical Scavenger ◽  
Radical Scavenger ◽  
Stroke Outcome ◽  
Stroke Patients ◽  
Treatment Results ◽  
Neuroprotective Effects ◽  
The Relationship

Background: Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome. However, the effect has not been examined in patients treated with edaravone, a frequently used free radical scavenger. We investigated whether the use of edaravone affected the relationship between UA levels and outcome in acute ischemic stroke. Methods: We retrospectively evaluated 1,114 consecutive ischemic stroke patients with premorbid modified Rankin Scale (mRS) scores <2 admitted within 24 h of onset (mean, 74 years; median UA levels, 333 μmol/L). We divided the patients into 2 groups using the median UA value as a cutoff, a low UA group (≤333 μmol/L; n = 566) and a high UA group (>333 μmol/L; n = 548), and compared their clinical characteristics and favorable outcomes (mRS <2) at 90 days. We investigated the associations between UA levels and 90-day stroke outcome in patients with and without edaravone treatment. Results: The high UA group had a higher proportion of men, hypertension, atrial fibrillation, and cardioembolic stroke than the low UA group. The high UA group also had a higher proportion of patients with mRS <2 at 90 days (61.5 vs. 54.1%, p = 0.013), but the significance was diminished in multivariate analysis (OR 1.30, 95% CI 0.94–1.71). In subgroup analysis, the high UA group without edaravone exhibited a higher proportion of patients with mRS <2 at 90 days than the low UA group (OR 2.87, 95% CI 1.20–7.16). The high UA group with edaravone did not exhibit this difference. Conclusions: In acute ischemic stroke, the favorable association between high UA levels and outcome at 90 days was not evident in patients treated with edaravone.

Perspective Treatment Goals for Brain Protection in Case of Acute Ischemia

2019 ◽  
pp. 9-13
Author(s):  
L. A. Dzyak ◽  
O. S. Tsurkalenko ◽  
V. M. Suk
Keyword(s):  
Ischemic Stroke ◽  
Free Radical ◽  
Free Radical Oxidation ◽  
Reperfusion Therapy ◽  
Free Radical Scavenger ◽  
Acute Ischemia ◽  
Radical Scavenger ◽  
Important Place ◽  
Radical Oxidation ◽  
Radical Processes

Abstract. Ischemic stroke initiates a cascade of biochemical reactions, among which the processes of free radical oxidation occupy a key place. The most important place in management this disease takes reperfusion therapy, the conduct of which is closely related to the problem of neuroprotection. Use of antioxidants is a promising direction for the treatment of ischemic stroke. They have antioxidant effects and could prevent free radical processes. Edaravone is a new low molecular weight free radical scavenger, which inhibits the ischemic cascade. The article provides an overview of studies on the effectiveness and safety of edaravone in patients with ischemic stroke.

Sign in / Sign up

Export Citation Format

Share Document